10.1371/journal.pone.0187289.g004 Matilde Forcella Matilde Forcella Monica Oldani Monica Oldani Samantha Epistolio Samantha Epistolio Stefania Freguia Stefania Freguia Eugenio Monti Eugenio Monti Paola Fusi Paola Fusi Milo Frattini Milo Frattini Evaluation of sialidase NEU3 effect on cell viability with or without gefitinib. Public Library of Science 2017 therapies sensitivity NSCLC cell viability NEU 3 EGFR point mutations TKI Non-Small Cell Lung Cancer Akt pathway NEU 3 overexpressing patients ERK pathway lung cancer cell lines plasma membrane-associated NEU 3 Adenocarcinoma sialidase NEU 3 EGFR pathways activation NEU 3 overexpression mucosa cell line Non-small cell lung cancer sialidase NEU 3 overexpression EGFR wild-type gene sequence 2017-10-31 17:47:15 Figure https://plos.figshare.com/articles/figure/Evaluation_of_sialidase_NEU3_effect_on_cell_viability_with_or_without_gefitinib_/5557231 <p>MTT test was performed on HSAEC1, HCC4006 and H1734 cell lines transfected with either the empty vector (mock) or pcDNA3.1-HsNEU3 and then treated or not with 27 nM or 1 μM gefitinib for 36 h <i>post</i>-transfection. Data were normalized on control cells transfected with the empty vector (A). Cell viabilities of mock and NEU3 transfected cells are reported after treatment with either 27 nM (B) or 1 μM gefitinib (C). Data were normalized on control cells without drug. Values are presented as means ± standard error (SE).</p>